Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
Christina Krienke, LAURA D. KOLB, Elif Diken, et al.
Science (2021) Vol. 371, Iss. 6525, pp. 145-153
Closed Access | Times Cited: 349

Showing 1-25 of 349 citing articles:

Lipid nanoparticles for mRNA delivery
Xucheng Hou, Tal Zaks, Róbert Langer, et al.
Nature Reviews Materials (2021) Vol. 6, Iss. 12, pp. 1078-1094
Open Access | Times Cited: 2234
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Namit Chaudhary, Drew Weissman, Kathryn A. Whitehead
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 11, pp. 817-838
Open Access | Times Cited: 992
Drug delivery systems for RNA therapeutics
Kalina Paunovska, David Loughrey, James E. Dahlman
Nature Reviews Genetics (2022) Vol. 23, Iss. 5, pp. 265-280
Open Access | Times Cited: 820
CAR T cells produced in vivo to treat cardiac injury
Joel G. Rurik, István Tombácz, Amir Yadegari, et al.
Science (2022) Vol. 375, Iss. 6576, pp. 91-96
Open Access | Times Cited: 794
MODOMICS: a database of RNA modification pathways. 2021 update
Pietro Boccaletto, Filip Stefaniak, Angana Ray, et al.
Nucleic Acids Research (2021) Vol. 50, Iss. D1, pp. D231-D235
Open Access | Times Cited: 627
Lipids and Lipid Derivatives for RNA Delivery
Yuebao Zhang, Changzhen Sun, Chang Wang, et al.
Chemical Reviews (2021) Vol. 121, Iss. 20, pp. 12181-12277
Open Access | Times Cited: 400
IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines
Siri Tähtinen, Ann-Jay Tong, Patricia Himmels, et al.
Nature Immunology (2022) Vol. 23, Iss. 4, pp. 532-542
Open Access | Times Cited: 343
Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines
Kellie D. Nance, Jordan L. Meier
ACS Central Science (2021) Vol. 7, Iss. 5, pp. 748-756
Open Access | Times Cited: 329
The landscape of mRNA nanomedicine
Xiangang Huang, Na Kong, Xingcai Zhang, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2273-2287
Open Access | Times Cited: 312
Unlocking the promise of mRNA therapeutics
Eduarde Rohner, Ran Yang, Kylie S. Foo, et al.
Nature Biotechnology (2022) Vol. 40, Iss. 11, pp. 1586-1600
Open Access | Times Cited: 306
Innate immune mechanisms of mRNA vaccines
R Verbeke, Michael J. Hogan, Karin Loré, et al.
Immunity (2022) Vol. 55, Iss. 11, pp. 1993-2005
Open Access | Times Cited: 236
Nucleic acid delivery for therapeutic applications
Akash Gupta, Jason L. Andresen, Rajith S. Manan, et al.
Advanced Drug Delivery Reviews (2021) Vol. 178, pp. 113834-113834
Closed Access | Times Cited: 225
COVID-19 mRNA vaccines: Platforms and current developments
Gábor Szabó, Azita J. Mahiny, Irena Vlatkovic
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1850-1868
Open Access | Times Cited: 206
RNA modifications: importance in immune cell biology and related diseases
Lian Cui, Rui Ma, Jiangluyi Cai, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 200
Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment
Yujing Huang, Xiaohan Guo, Yi Wu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 147
Immune cell compartmentalization for brain surveillance and protection
Tommaso Croese, Giulia Castellani, Michal Schwartz
Nature Immunology (2021) Vol. 22, Iss. 9, pp. 1083-1092
Closed Access | Times Cited: 139
Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting
Marc Charabati, Michael A. Wheeler, Howard L. Weiner, et al.
Cell (2023) Vol. 186, Iss. 7, pp. 1309-1327
Open Access | Times Cited: 120
Non-liver mRNA Delivery
David Loughrey, James E. Dahlman
Accounts of Chemical Research (2021) Vol. 55, Iss. 1, pp. 13-23
Closed Access | Times Cited: 116
Targeted Immunotherapy for Autoimmune Disease
Seung Min Jung, Wan‐Uk Kim
Immune Network (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 110
mRNA vaccines in disease prevention and treatment
Gang Zhang, Tianyu Tang, Yinfeng Chen, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 110
Circular RNA vaccine in disease prevention and treatment
Dun Niu, Yaran Wu, Jiqin Lian
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 99
Regulating trained immunity with nanomedicine
Mandy M. T. van Leent, Bram Priem, David P. Schrijver, et al.
Nature Reviews Materials (2022) Vol. 7, Iss. 6, pp. 465-481
Open Access | Times Cited: 83
Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses
Menglin Wang, Benoı̂t Rousseau, Kunyu Qiu, et al.
Nature Biotechnology (2023) Vol. 42, Iss. 8, pp. 1263-1274
Closed Access | Times Cited: 80
Carrier strategies boost the application of CRISPR/Cas system in gene therapy
Zunkai Xu, Qingnan Wang, Haiping Zhong, et al.
Exploration (2022) Vol. 2, Iss. 2
Open Access | Times Cited: 79
mRNA-based therapeutics: looking beyond COVID-19 vaccines
Hamideh Parhiz, Elena N. Atochina‐Vasserman, Drew Weissman
The Lancet (2024) Vol. 403, Iss. 10432, pp. 1192-1204
Closed Access | Times Cited: 77
Page 1 - Next Page

Scroll to top